Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126778369> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3126778369 abstract "Abstract Objective. Interleukin-2 (IL-2) is effective and well tolerated in patients with systemic lupus erythematosus (SLE). However, patient response to IL-2 therapy varies. Therefore, biomarkers are needed to efficiently identify patients who may respond well to IL-2 treatment. We investigated clinical and immunological biomarkers to predict low-dose IL-2 responses. Methods. A pooled post-hoc analysis was performed in SLE patients who received low-dose IL-2 treatment in two clinical trials. Factors predicting responses in clinical and T-cell subset changes were evaluated by logistic regression. Good response (GR) and poor response (PR) were defined according to whether patients achieved or did not achieve an SLE Responder Index-4 (SRI-4), respectively. Results. A good response at 68% of patients was achieved in the lower Treg group, compared to 0% in the higher Treg group. A good response at 68% was achieved in patients with lower Treg, compared to 0% in patients with higher Treg. In comparison to PR, GR was more strongly associated with low Treg proportions at baseline (12.85±6.07% vs. 9.43±2.82%, P <0.01). There were more patients with skin rash in the GR group than in the PR group (68.75% vs. 30.77%, P =0.042). Multivariate analysis showed that low Treg proportions and skin rash presence were both independently associated with GR to low-dose IL-2 treatment. A nomogram to identify GR probability exhibited a clear discrimination (concordance index, 0.812; 95% confidence interval, 0.64-0.97). Based on the area under the receiver operating characteristic (ROC) curve (AUC) of 0.813, the specificity of a low regulatory T cells (Tregs) proportion (≤13.35%) plus skin rash to predict GR to IL-2 therapy was 100%, with a sensitivity of 68.75%. Conclusion. A low Treg proportion and skin rash indicate GR to low-dose IL-2 treatment in SLE patients. Trial registration number ClinicalTrials.gov Registries ((NCT02465580 and NCT02084238)." @default.
- W3126778369 created "2021-02-15" @default.
- W3126778369 creator A5001081618 @default.
- W3126778369 creator A5030149457 @default.
- W3126778369 creator A5039342892 @default.
- W3126778369 creator A5045614365 @default.
- W3126778369 creator A5070139617 @default.
- W3126778369 creator A5075424371 @default.
- W3126778369 creator A5083019914 @default.
- W3126778369 date "2021-01-07" @default.
- W3126778369 modified "2023-09-23" @default.
- W3126778369 title "Therapeutic Responses and Predictors of Low-Dose Interleukin-2 in Systemic Lupus Erythematosus" @default.
- W3126778369 doi "https://doi.org/10.21203/rs.3.rs-138441/v1" @default.
- W3126778369 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34001306" @default.
- W3126778369 hasPublicationYear "2021" @default.
- W3126778369 type Work @default.
- W3126778369 sameAs 3126778369 @default.
- W3126778369 citedByCount "0" @default.
- W3126778369 crossrefType "posted-content" @default.
- W3126778369 hasAuthorship W3126778369A5001081618 @default.
- W3126778369 hasAuthorship W3126778369A5030149457 @default.
- W3126778369 hasAuthorship W3126778369A5039342892 @default.
- W3126778369 hasAuthorship W3126778369A5045614365 @default.
- W3126778369 hasAuthorship W3126778369A5070139617 @default.
- W3126778369 hasAuthorship W3126778369A5075424371 @default.
- W3126778369 hasAuthorship W3126778369A5083019914 @default.
- W3126778369 hasBestOaLocation W31267783691 @default.
- W3126778369 hasConcept C126322002 @default.
- W3126778369 hasConcept C151956035 @default.
- W3126778369 hasConcept C159654299 @default.
- W3126778369 hasConcept C203014093 @default.
- W3126778369 hasConcept C2775915377 @default.
- W3126778369 hasConcept C2778570526 @default.
- W3126778369 hasConcept C2778690821 @default.
- W3126778369 hasConcept C34626388 @default.
- W3126778369 hasConcept C44249647 @default.
- W3126778369 hasConcept C535046627 @default.
- W3126778369 hasConcept C71924100 @default.
- W3126778369 hasConcept C74172505 @default.
- W3126778369 hasConcept C90924648 @default.
- W3126778369 hasConceptScore W3126778369C126322002 @default.
- W3126778369 hasConceptScore W3126778369C151956035 @default.
- W3126778369 hasConceptScore W3126778369C159654299 @default.
- W3126778369 hasConceptScore W3126778369C203014093 @default.
- W3126778369 hasConceptScore W3126778369C2775915377 @default.
- W3126778369 hasConceptScore W3126778369C2778570526 @default.
- W3126778369 hasConceptScore W3126778369C2778690821 @default.
- W3126778369 hasConceptScore W3126778369C34626388 @default.
- W3126778369 hasConceptScore W3126778369C44249647 @default.
- W3126778369 hasConceptScore W3126778369C535046627 @default.
- W3126778369 hasConceptScore W3126778369C71924100 @default.
- W3126778369 hasConceptScore W3126778369C74172505 @default.
- W3126778369 hasConceptScore W3126778369C90924648 @default.
- W3126778369 hasLocation W31267783691 @default.
- W3126778369 hasOpenAccess W3126778369 @default.
- W3126778369 hasPrimaryLocation W31267783691 @default.
- W3126778369 hasRelatedWork W2088179268 @default.
- W3126778369 hasRelatedWork W2559492968 @default.
- W3126778369 hasRelatedWork W2768547807 @default.
- W3126778369 hasRelatedWork W3119851179 @default.
- W3126778369 hasRelatedWork W4200076619 @default.
- W3126778369 hasRelatedWork W4210805376 @default.
- W3126778369 hasRelatedWork W4285495457 @default.
- W3126778369 hasRelatedWork W4311602910 @default.
- W3126778369 hasRelatedWork W4366335804 @default.
- W3126778369 hasRelatedWork W4366602962 @default.
- W3126778369 isParatext "false" @default.
- W3126778369 isRetracted "false" @default.
- W3126778369 magId "3126778369" @default.
- W3126778369 workType "article" @default.